Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG

Fig. 3

MS-275 enhances NK cell-mediated cytotoxicity against DMG cells. A-B Luciferase-engineered TT150630 and TT190326 cell lines were treated with DMSO or 1µM MS-275 for 2 days and cocultured with NK-92MI cells at the indicated E:T ratios. After 4 h of incubation, bioluminescence was measured, and NK cell-induced cytotoxicity (%) was calculated and plotted. C-F DMG cells were treated with MS-275 (1µM) for 2 days, stained with calcein AM, and cocultured with NK-92MI cells in 96-well plates at a 1:1 ratio (TT190326, TT150630 and TT170720) or a 5:1 ratio (TT150728). After incubation for 4 h, fluorescence images were captured using an inverted microscope. Images of DMG cell lines showing a reduction in fluorescence (indicating cell death) are presented (left). Calcein AM-stained DMG cells without NK-92MI cells served as controls. The percentage (%) of cells undergoing NK cell-induced cytotoxicity was calculated and plotted (right). Statistical significance was assessed via Student’s t test, with *p < 0.05 and **p < 0.01. Scale bars, 500 μm

Back to article page